BATTLEFIELD WOUND INFECTION PREVENTION AND TREATMENT (BWI P&T): BARRIER COMBINATION PRODUCT DEVELOPMENT HT9427-26-RFI-BWI-PT
Summary
AI-generated · Dec 04, 2025Market research is being conducted to determine whether a commercial barrier combination product can meet requirements for battlefield wound infection prevention and treatment. This barrier component is part of the Battlefield Wound Infection Prevention and Treatment (BWI P&T) program, which uses a Family of Systems approach to develop multiple medical materiel solutions for austere environments where medical products are limited and evacuation may be prolonged. The barrier product is expected to be used at the point of injury and across the continuum of care from austere battlefield settings to hospital care.
The barrier combination product must meet the minimum essential characteristics defined in the MECS. The RFI includes attachments with technical readiness level references, company and product information, and the MECS. Interested parties may respond electronically in accordance with the attached instructions.
The Government is conducting market research to determine whether a commercial solution can be provided to meet requirements for battlefield wound infection prevention and treatment: barrier combination product. This market research may also assist with the further development and/or refinement of the requirements. Objective and Purpose/Scope: DHA s OPMED WPAC has a requirement to develop, deliver, and field medical products that address battlefield wounds and subsequent bacterial and fungal infections. The Battlefield Wound Infection Prevention and Treatment (BWI P&T) program is using a Family of Systems (FoS) approach that aims to develop multiple medical materiel solutions that are most relevant for use in austere environments where medical products may be limited and evacuation may be prolonged. This RFI seeks responses to the barrier combination component of this FoS only. Although there is an emphasis on use at the point of injury, this capability will likely be used across roles of care spanning the austere battlefield environment to hospital care settings. The barrier combination product is expected to be one of many components of the FoS that will provide novel solutions to the DoD and commercial market with respect to wound care and infection prevention. The barrier combination product must have the following minimum essential characteristics: Please refer to Attachment 3 - Minimum Essential Characteristics (MECS) North American Industry Classification System (NAICS) Code: Unknown RFI Attachments: The following documents are attached to the RFI Attachment 1: Technical Readiness Level (TRL) (Reference Only) Attachment 2: Company & Product Information Attachment 3: Minimum Essential Characteristics (MECS) Response Due Date: Interested parties shall submit the RFI response electronically by 2:00pm Eastern on January 20, 2026, via e-mail to: Please review Attachments 1, 2, and 3 as well as RFI for BWI PT Barrier Attachment for further instructions
From Sources Sought posted on Dec 03, 2025Notice history
1-
Sources Sought LATEST Posted Dec 03, 2025
Details
Award Information
Not yet awarded
Contacts
Agency
Place of Performance
USA